Literature DB >> 25146988

Molecular mechanism of formation of cortical opacity in CRYAAN101D transgenic mice.

Shylaja M Hegde1, Kiran Srivastava1, Ekta Tiwary1, Om P Srivastava1.   

Abstract

PURPOSE: The CRYAAN101D transgenic mouse model expressing deamidated αA-crystallin (deamidation at N101 position to D) develops cortical cataract at the age of 7 to 9 months. The present study was carried out to explore the molecular mechanism that leads to the development of cortical opacity in CRYAAN101D lenses.
METHODS: RNA sequence analysis was carried out on 2- and 4-month-old αA-N101D and wild type (WT) lenses. To understand the biologic relevance and function of significantly altered genes, Ingenuity Pathway Analysis (IPA) was done. To elucidate terminal differentiation defects, immunohistochemical, and Western blot analyses were carried out.
RESULTS: RNA sequence and IPA data suggested that the genes belonging to gene expression, cellular assembly and organization, and cell cycle and apoptosis networks were altered in N101D lenses. In addition, the tight junction signaling and Rho A signaling were among the top three canonical pathways that were affected in N101D mutant. Immunohistochemical analysis identified a series of terminal differentiation defects in N101D lenses, specifically, increased proliferation and decreased differentiation of lens epithelial cells (LEC) and decreased denucleation of lens fiber cells (LFC). The expression of Rho A was reduced in different-aged N101D lenses, and, conversely, Cdc42 and Rac1 expressions were increased in the N101D mutants. Moreover, earlier in development, the expression of major membrane-bound molecular transporter Na,K-ATPase was drastically reduced in N101D lenses.
CONCLUSIONS: The results suggest that the terminal differentiation defects, specifically, increased proliferation and decreased denucleation are responsible for the development of lens opacity in N101D lenses. Copyright 2014 The Association for Research in Vision and Ophthalmology, Inc.

Entities:  

Keywords:  alpha A crystallin; cortical opacity; deamidation; denucleation

Mesh:

Substances:

Year:  2014        PMID: 25146988      PMCID: PMC4197685          DOI: 10.1167/iovs.14-14623

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  61 in total

1.  A transgenic mouse model for human autosomal dominant cataract.

Authors:  Cheng-Da Hsu; Steven Kymes; J Mark Petrash
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-05       Impact factor: 4.799

2.  Binding of Src to Na+/K+-ATPase forms a functional signaling complex.

Authors:  Jiang Tian; Ting Cai; Zhaokan Yuan; Haojie Wang; Lijun Liu; Michael Haas; Elena Maksimova; Xin-Yun Huang; Zi-Jian Xie
Journal:  Mol Biol Cell       Date:  2005-11-02       Impact factor: 4.138

3.  The alpha 1 isoform of Na,K-ATPase regulates cardiac contractility and functionally interacts and co-localizes with the Na/Ca exchanger in heart.

Authors:  Iva Dostanic; Jo El J Schultz; John N Lorenz; Jerry B Lingrel
Journal:  J Biol Chem       Date:  2004-10-14       Impact factor: 5.157

4.  Actin filament organization regulates the induction of lens cell differentiation and survival.

Authors:  Gregory F Weber; A Sue Menko
Journal:  Dev Biol       Date:  2006-04-07       Impact factor: 3.582

Review 5.  The role of the lens actin cytoskeleton in fiber cell elongation and differentiation.

Authors:  P Vasantha Rao; Rupalatha Maddala
Journal:  Semin Cell Dev Biol       Date:  2006-11-01       Impact factor: 7.727

6.  Inhibition of RhoA GTPase activity enhances hematopoietic stem and progenitor cell proliferation and engraftment.

Authors:  Gabriel Ghiaur; Andrew Lee; Jeff Bailey; Jose A Cancelas; Yi Zheng; David A Williams
Journal:  Blood       Date:  2006-05-18       Impact factor: 22.113

7.  Transgenic overexpression of connexin50 induces cataracts.

Authors:  June Chung; Viviana M Berthoud; Layne Novak; Rebecca Zoltoski; Benjamin Heilbrunn; Peter J Minogue; Xiaoqin Liu; Lisa Ebihara; Jer Kuszak; Eric C Beyer
Journal:  Exp Eye Res       Date:  2007-01-10       Impact factor: 3.467

8.  Age-related changes in human crystallins determined from comparative analysis of post-translational modifications in young and aged lens: does deamidation contribute to crystallin insolubility?

Authors:  P A Wilmarth; S Tanner; S Dasari; S R Nagalla; M A Riviere; V Bafna; P A Pevzner; L L David
Journal:  J Proteome Res       Date:  2006-10       Impact factor: 4.466

9.  Rho GDP dissociation inhibitor-mediated disruption of Rho GTPase activity impairs lens fiber cell migration, elongation and survival.

Authors:  Rupalatha Maddala; Lixing W Reneker; Bhavana Pendurthi; Ponugoti V Rao
Journal:  Dev Biol       Date:  2008-01-03       Impact factor: 3.582

Review 10.  Rho GTPases and cell migration.

Authors:  A J Ridley
Journal:  J Cell Sci       Date:  2001-08       Impact factor: 5.285

View more
  4 in total

1.  UPR Activation and the Down-Regulation of α-Crystallin in Human High Myopia-Related Cataract Lens Epithelium.

Authors:  Jing Yang; Sheng Zhou; Jianjun Gu; Minfei Guo; Honghui Xia; Yizhi Liu
Journal:  PLoS One       Date:  2015-09-09       Impact factor: 3.240

2.  Upregulation of multiple signaling pathways by Dock5 deletion in epithelial cells.

Authors:  Xiaohe Xu; Hisayoshi Yoshizaki; Yasuhito Ishigaki; Eri Kubo; Hiroshi Minato; Etsuko Kiyokawa
Journal:  Mol Vis       Date:  2017-12-31       Impact factor: 2.367

3.  Increased Association of Deamidated αA-N101D with Lens membrane of transgenic αAN101D vs. wild type αA mice: potential effects on intracellular ionic imbalance and membrane disorganization.

Authors:  Om Srivastava; Kiran Srivastava; Roy Joseph; Landon Wilson
Journal:  BMC Ophthalmol       Date:  2020-12-10       Impact factor: 2.209

4.  Probing the changes in gene expression due to α-crystallin mutations in mouse models of hereditary human cataract.

Authors:  Usha P Andley; Eric Tycksen; Brittney N McGlasson-Naumann; Paul D Hamilton
Journal:  PLoS One       Date:  2018-01-16       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.